PFE

Pfizer Inc. 10-Q Summary: Quarter Ended June 27, 2004

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 27, 2004, and the six-month period ended on the same date. Pfizer is a global research-based pharmaceutical company. The reporting period reflects the full impact of the Pharmacia acquisition (completed April 2003) and includes the recent acquisition of Esperion Therapeutics, Inc. (February 2004). The company operates through three primary segments: Pharmaceutical, Consumer Healthcare, and Animal Health.

Key Financial Metrics

Note: Total Debt includes $12,204 million in short-term borrowings and $6,765 million in long-term debt. Cash and short-term investments are derived from the balance sheet ($652M cash + $16,831M short-term investments).

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 24% in the quarter and 35% year-to-date compared to 2003. This growth is primarily driven by the inclusion of Pharmacia results for the full period (vs. partial period in 2003), strong performance of key products (Lipitor, Celebrex, Zoloft), and favorable foreign exchange impacts.
• Profitability: Net income swung from a loss of $3,591 million in the prior year quarter to a profit of $2,863 million. This reversal is largely due to the absence of a $5,130 million non-cash charge for in-process research and development (IPR&D) related to the Pharmacia acquisition recorded in 2003.
• Discontinued Operations: In 2003, the company recorded significant gains ($2,285 million net of tax) from the sale of Adams confectionery and Schick-Wilkinson Sword businesses. In 2004, discontinued operations contributed only $32 million net of tax, reflecting the sale of smaller non-core units (diagnostics, surgical ophthalmic, and European generics).
• Acquisitions: Pfizer recorded a $955 million IPR&D charge in the first six months of 2004, primarily related to the Esperion acquisition ($920 million).

Guidance, Outlook, and Risks

• Revised Guidance: Management revised full-year 2004 revenue estimates downward to $52.5–$53.0 billion (from $54 billion) due to market conditions and foreign exchange. However, GAAP net income guidance was revised upward to $12.1 billion (from $11.9 billion) and diluted EPS to $1.58 (from $1.55), driven by the timing of merger-related costs.
• Adjusted Income: The company expects full-year Adjusted Income of $16.3 billion and adjusted diluted EPS of $2.13.
• R&D Spending: Planned R&D spending for 2004 is approximately $7.6 billion.
• Legal Proceedings: Significant litigation includes patent disputes regarding Xalatan (court ruled in Pfizer's favor, blocking generic until 2011) and Accupril (injunction granted until 2007). The company is also defending product liability suits related to Lipitor, Zoloft, and Hormone-Replacement Therapy, as well as ongoing asbestos claims.
• Merger Integration: Total merger-related expenditures for 2003–2005 are expected to be approximately $6.0 billion. Cost synergies from the Pharmacia acquisition totaled over $1.7 billion in the first six months of 2004.

Investor Verification Checklist

• Patent Expirations: Verify the status of patent protections for major revenue drivers like Lipitor, Zoloft, and Neurontin, and the impact of recent court rulings on generic entry.
• Discontinued Operations: Confirm the final proceeds and tax implications of the divestitures of the diagnostics, surgical ophthalmic, and European generic businesses.
• Merger Costs: Monitor the timing and classification of remaining merger-related restructuring costs and their impact on GAAP vs. Adjusted Income.
• Legal Reserves: Review the adequacy of accruals for ongoing litigation, particularly regarding Neurontin promotion settlements and asbestos claims.
• Foreign Exchange: Assess the sensitivity of future revenue guidance to fluctuations in the U.S. dollar, given the significant international revenue base.